A Phase Ib Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment

Trial Profile

A Phase Ib Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs NUC 3373 (Primary) ; Bevacizumab; Cetuximab; Folinic acid; Irinotecan; Oxaliplatin; Panitumumab
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors NuCana
  • Most Recent Events

    • 14 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top